Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) plans to host a live conference call and webcast on November 14, 2022, at 8:30 a.m. ET, to discuss its third quarter 2022 financial results. The call will provide updates on the company's clinical-stage pipeline, including treatments for conditions such as myelodysplastic syndrome and acute myeloid leukemia. Participants can register for the call here and access the webcast on Syros' website.

Positive

• Upcoming conference call providing third quarter financial results.
• Robust clinical-stage pipeline with multiple innovative therapies.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update.

To access the live conference call, please register using the conference link here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A webcast of the call will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005013/en/

Syros:

Karen Hunady

Director of Corporate Communications & Investor Relations

1-857-327-7321

khunady@syros.com

Media:

Brittany Leigh, Ph.D.

LifeSci Communications, LLC

+1-813-767-7801

bleigh@lifescicomms.com

Investors:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

When will Syros Pharmaceuticals announce its Q3 2022 earnings?

Syros Pharmaceuticals will announce its Q3 2022 earnings on November 14, 2022.

How can I access the Syros Pharmaceuticals conference call?

You can access the conference call by registering here.

What is the focus of Syros Pharmaceuticals' clinical pipeline?

Syros Pharmaceuticals focuses on developing treatments for myelodysplastic syndrome, acute myeloid leukemia, and other cancers.

Where can I find the webcast for Syros Pharmaceuticals' earnings call?

The webcast will be available on the Investors & Media section of Syros' website.